When administered subcutaneously, semaglutide binds to GLP-1 receptors located throughout the body, including areas that influence appetite control
Tirzepatide (highest doses in SURMOUNT-1) produced average losses near or above 20%, depending on dose, with clear dose-response effects in pivotal trials
The newer drugs represent a genuine breakthrough, offering results that approach bariatric surgery outcomes without requiring invasive procedures
[PubMed: 36507900] Randomized Controlled Trials Ongoing Trial Economic Evaluations Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services
But while depression and suicidal ideation are mentioned on the US document, the UK version omits them and so I stayed on the injections for another month
This is not medical advice or a provider-patient relationship under Florida law